Headache Center, Geriatrics Clinic, SS Annunziata Hospital of Chieti, Chieti, Italy.
Department of Medicine and Science of Aging, Medical Clinic, SS. Annunziata Hospital of Chieti, "G. D'Annunzio" University of Chieti, Chieti, Italy.
Expert Opin Emerg Drugs. 2023 Dec;28(4):233-240. doi: 10.1080/14728214.2023.2288334. Epub 2023 Dec 26.
Significant advances in migraine research have contributed to the development of new drugs for the treatment of migraine. Monoclonal antibodies (mAbs) against Calcitonin Gene-Related Peptide (CGRP) or its receptor and CGRP receptor antagonists (gepants) have been associated with a good safety profile and resulted in an overall efficacy in reducing the number of monthly migraine days both in episodic and chronic forms of migraine.
The results from main investigation studies (phase 2 or 3) of CGRP-targeting drugs (both anti-CGRP mAbs and gepants) are reported in this expert-opinion review.
The introduction of new drugs targeting CGRP is a significant breakthrough in the migraine field, and represents a new generation of therapeutic agents that are available to manage migraine. The evaluation of efficacy and safety in the long-term follow-up and the development of trials comparing the available drugs could improve the current knowledge. The economic sustainability of these drugs remains to be clarified, and a cost-cutting campaign should be promoted based on the high burden of migraine.
偏头痛研究的重大进展促进了治疗偏头痛新药的发展。降钙素基因相关肽（CGRP）或其受体的单克隆抗体（mAbs）和 CGRP 受体拮抗剂（ gepants）与良好的安全性相关，并在减少每月偏头痛天数方面总体有效，无论是在偏头痛的发作性还是慢性形式中。
本文对靶向 CGRP 的药物（抗 CGRP mAbs 和 gepants）的主要研究（2 期或 3 期）结果进行了专家意见综述。
靶向 CGRP 的新药的问世是偏头痛领域的重大突破，代表了新一代治疗药物，可用于治疗偏头痛。在长期随访中评估疗效和安全性，并开展比较现有药物的试验，可以增进目前的认识。这些药物的经济可持续性仍有待阐明，应基于偏头痛的高负担来开展一项成本削减运动。
